Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary 
Medicus Pharma marks Nasdaq milestone as it advances Phase 2 clinical programs
Medicus Pharma (NASDAQ:MDCX) has marked the one-year anniversary of its Nasdaq listing on Thursday by ringing the Opening Bell at the Nasdaq MarketSite in New York's Times Square. CEO Dr Raza Bokhari said the company was honored with the opportunity, describing the milestone as a reflection of Medicus' progress since going public and its continued focus on disciplined execution across a streamlined and strategically selected clinical portfolio.
Medicus Pharma lowers royalty burden on prostate cancer drug Teverelix
Medicus Pharma (NASDAQ:MDCX) said on Thursday its subsidiary Antev Ltd has amended a licensing agreement with UK-based medical research organization LifeArc, reducing future royalties tied to the experimental drug Teverelix, a move the company said improves the asset's long-term commercial profile. Under the revised agreement, royalties payable on worldwide net sales of Teverelix have been cut to 2% from about 4%, with the royalty term clarified on a country-by-country basis, Medicus said.
Medicus Pharma advances Teverelix program, set to present Phase 1 data at AACE Annual Meeting
Medicus Pharma (NASDAQ:MDCX) announced that it will present new Phase 1 clinical data on its long-acting gonadotropin-releasing hormone (GnRH) antagonist Teverelix at the American Association of Clinical Endocrinology (AACE) Annual Meeting in April 2026. The company said its abstract, titled “Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodynamics, Bone Turnover and Safety in Two Phase 1 Studies in Healthy Female Volunteers,” has been accepted for e-Poster presentation at the meeting, which will be held April 22 to 24 in Las Vegas.
Medicus Pharma signs non-binding AI collaboration to support clinical trials
Medicus Pharma (NASDAQ:MDCX) said on Monday it has entered into a letter of intent with Reliant AI Inc to collaborate on the development of an artificial-intelligence-powered data analytics platform aimed at improving the execution of its clinical trials. The Nasdaq-listed biotechnology company said the proposed platform would integrate Reliant's generative AI technology with Medicus' clinical, operational and proprietary datasets to support data-driven decision-making across its development pipeline.
Medicus Pharma completes SkinJect trial enrolment – ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Dr Raza Bokhari talked with Proactive about the company completing patient enrollment in its SkinJect clinical trial. The company has now enrolled 90 patients across nine sites in the United States as part of its clinical development program for Skinject, a novel, noninvasive treatment for non-melanoma skin diseases, specifically basal cell carcinoma.
Medicus Pharma completes enrollment for Phase 2 basal cell carcinoma study
Medicus Pharma (NASDAQ:MDCX) announced that it has completed enrollment of 90 patients in its Phase 2 clinical study evaluating a non-invasive treatment for basal cell carcinoma (BCC) of the skin. The study, known as SKNJCT-003, is assessing the safety and efficacy of the company's doxorubicin microneedle array (D-MNA) in patients with nodular BCC.
Medicus Pharma names president Carolyn Bonner as new CFO
Medicus Pharma (NASDAQ:MDCX) announced that Carolyn Bonner, who currently serving as the company's president, has been appointed to the role of chief financial officer (CFO). Bonner has been acting CFO since September 12, filling the role during the medical leave of former finance chief Jim Quinlan, who has now resigned from the company for health reasons.
Medicus Pharma spotlights new approaches to prostate and skin cancer during Men's Health Awareness Month
Medicus Pharma (NASDAQ:MDCX) marked Men's Health Awareness Month on Monday by underscoring new academic research focused on improving treatment options for prostate and skin cancers, two of the most common cancers affecting men. The biotechnology and life sciences company is advancing the clinical development of novel therapeutic candidates, including non-invasive treatments for basal cell skin cancer and next-generation therapies for advanced prostate conditions.
Medicus Pharma seeks FDA priority voucher for non-invasive skin cancer therapy
Medicus Pharma (NASDAQ:MDCX) said on Monday it has applied for a US Food and Drug Administration Commissioner's National Priority Voucher (CNPV) to accelerate review of SkinJect, its investigational microneedle patch designed to non-invasively treat basal cell carcinoma (BCC). The application includes a Statement of Interest outlining how SkinJect's Doxorubicin Microneedle Array (D-MNA) aligns with the FDA's national priorities, which focus on improving cancer care access, affordability and options for patients with rare diseases, the company said.
Medicus Pharma adds UK site to Skinject study - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the latest expansion of the company's Phase 2 clinical trial for Skinject, its lead noninvasive therapy for basal cell carcinoma. The company recently received approval from the UK Regulatory Authority to include UK sites in the ongoing Skinject 003 study.
Medicus Pharma secures UK approval to expand Phase 2 trial of non-invasive skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) said on Thursday it has received full regulatory and ethical approvals in the UK to expand its ongoing Phase 2 clinical trial evaluating its Doxorubicin Microneedle Array (D-MNA) treatment for basal cell carcinoma (BCC), a common form of skin cancer. The UK's Medicines and Healthcare products Regulatory Agency, Health Research Authority and Wales Research Ethics Committee granted the approvals, allowing Medicus to add clinical sites in the country to its ongoing study (SKNJCT-003), which is already underway across nine sites in the US.
Medicus Pharma eyes compassionate use approval of Skinject for Gorlin Syndrome - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's recent steps to expand compassionate access to Skinject, its lead non-invasive treatment for non-melanoma skin diseases. The initiative involves a partnership with the Gorlin Syndrome Alliance, aiming to address unmet needs for patients living with this rare genetic condition.
